Intensity Therapeutics, Inc.

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
4 ^USD	+6.38%		+3.63%	-53.33%

05-10	Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	MT
05-10	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	CI

Intensity Therapeutics, Inc.(NasdaqCM:INTS) added to S&P TMI Index

September 18, 2023 at 12:00 am

Latest news about Intensity Therapeutics, Inc.

Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	05-10	MT
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	05-10	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	04-19	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	01-03	DJ
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	12-25	CI
Certain Warrants of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	12-25	CI
Certain Stock Options of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	12-25	CI
Intensity Therapeutics Names Joseph Talamo as Finance Chief	12-12	MT
Intensity Therapeutics, Inc. Announces Appointment of Joseph Talamo as Chief Financial Officer	12-12	CI
Sector Update: Health Care Stocks Rise Late Afternoon	12-08	MT
Sector Update: Health Care	12-08	MT
Top Midday Gainers	12-08	MT
Intensity Therapeutics Says Breast Cancer Treatment Showed Tumor Necrosis in Phase 2 Trial; Shares Jump	12-08	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Intensity Therapeutics, Inc. Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023	11-02	CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) added to S&P TMI Index	23-09-18	CI
Intensity Therapeutics Gets Orphan Drug Label for Three Ingredients in INT230-6	23-09-07	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Benchmark Initiates Intensity Therapeutics at Speculative Buy With $12 Price Target	23-07-18	MT
Intensity Therapeutics Raises $19.5 Million From Public Offering	23-07-05	MT
Intensity Therapeutics, Inc.(NasdaqCM:INTS) added to NASDAQ Composite Index	23-07-03	CI
Intensity Therapeutics Shares Surge in Nasdaq Debut After IPO Pricing	23-06-30	MT
Intensity Therapeutics Prices Upsized IPO at $5 per Share	23-06-30	MT

Chart Intensity Therapeutics, Inc.

Duration

Period

More charts

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patientâs cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4 USD

Average target price

12 USD

Spread / Average Target

+200.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTENSITY THERAPEUTICS, INC.	-53.33%	54.84M
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research